


PRI-724

Cat. No.:	OB0225WX-1712
Appearance:	Solid
Purity:	≥99%
Identity:	Confirmed by NMR, and LC-MS.
Size:	1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg

This product is for research use only and is not intended for diagnostic use.

Product Overview

Description	PRI-724 is a second-generation selective small molecule designed to inhibit the specific interaction between CBP and β -catenin.
--------------------	--



Synonym	C-82 prodrug; Foscenvivint; 1422253-38-0; PRI724; (S,S)-ICG-001; [4-[[[(6S,9S,9aS)-1-(benzylcarbamoyl)-2,9-dimethyl-4,7-dioxo-8-(quinolin-8-ylmethyl)-3,6,9,9a-tetrahydropyrazino[2,1-c][1,2,4]triazin-6-yl]methyl]phenyl] dihydrogen phosphate; (6S,9S,9aS)-Hexahydro-2,9-dimethyl-4,7-dioxo-N-(phenylmethyl)-6-[[4-(phosphonoxy)phenyl]methyl]-8-(8-quinolinylmethyl)-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide; 2H-P yrazino(2,1-C)(1,2,4)triazine-1(6H)-carboxamide, hexahydro-2,9-dimethyl-4,7-dioxo-N-(phenylmethyl)-6-((4-(phosphonoxy)phenyl)methyl)-8-(8-quinolinylmethyl)-, (6S,9S,9aS)-; 1422253-38-0 (PRI-724); 4-(((6S,9S,9aS)-1-(Benzylcarbamoyl)-2,9-dimethyl-4,7-dioxo-8-(quinolin-8-yl)methyl)octahydro-2hpyrazino(2,1-C)(1,2,4)triazin-6-yl)methyl]phenyl dihydrogen phosphate; 4-(((6S,9S,9aS)-1-(benzylcarbamoyl)-2,9-dimethyl-4,7-dioxo-8-(quinolin-8-yl)methyl)octahydro-2H-pyrazino[2,1-c][1,2,4]triazin-6-yl)methyl]phenyl dihydrogen phosphate; (4-(((6S,9S,9aS)-1-(benzylcarbamoyl)-2,9-dimethyl-4,7-dioxo-8-(quinolin-8-yl)methyl)octahydro-1H-pyrazino(2,1-c)(1,2,4)triazin-6-yl)methyl)phenoxy)phosphonic acid; (4-(((6S,9S,9aS)-1-(benzylcarbamoyl)-2,9-dimethyl-4,7-dioxo-8-(quinolin-8-yl)methyl)octahydro-1H-pyrazino[2,1-c][1,2,4]triazin-6-yl)methyl)phenoxy)phosphonic acid; 4-(((6S,9S,9aS)-1-(Benzylcarbamoyl)-2,9-dimethyl-4,7-dioxo-8-(quinolin-8-yl)methyl)octahydro-1H-pyrazino[2,1-c][1,2,4]triazin-6-yl)methyl]phenyl dihydrogen phosphate
CAS No.	1422253-38-0
Compound CID	71509318
Formula	C ₃₃ H ₃₅ N ₆ O ₇ P
Formula Weight	658.64

Specification

Relative Density	1.48 g/cm ³
IUPAC Name	[4-[[[(6S,9S,9aS)-1-(Benzylcarbamoyl)-2,9-dimethyl-4,7-dioxo-8-(quinolin-8-ylmethyl)-3,6,9,9a-tetrahydropyrazino[2,1-c][1,2,4]triazin-6-yl]methyl]phenyl] dihydrogen phosphate
InChI	InChI=1S/C33H35N6O7P/c1-22-31-38(29(40)21-36(2)39(31)33(42)35-19-24-8-4-3-5-9-24)28(18-23-13-15-27(16-14-23)46-47(43,44)45)32(41)37(22)20-26-11-6-10-25-12-7-17-34-30(25)26/h3-17,22,28,31H,18-21H2,1-2H3,(H,35,42)(H2,43,44,45)/t22-,28-,31-/m0/s1
InChI Key	VHOZWHQPEJGPCC-AZXYEMZSA-N
SMILES string	C[C@H]1[C@H]2N([C@H](C(=O)N1CC3=CC=CC4=C3N=CC=C4)CC5=CC=C(C(=C5)OP(=O)(O)O)C(=O)CN(N2C(=O)NCC6=CC=CC=C6)C
Stability	3 years in powder form.
Storage	Storage at -20°C.
Applications	PRI-724 is used in translational research as a specific inhibitor of the beta-catenin/CBP interaction to investigate the modulation of fibrotic signaling and tumor growth.

Library Information

Target	Wnt/β-Catenin
Receptor	Wnt/β-Catenin
Pathways	Cytoskeletal signaling; Stem cells
Plate Number	AOCL-22
Plate Location	h7
Empty Location	a1-h1; a12-h12
Container	96-well plate
Formulation	10mM DMSO
DMSO Max Solubility	55 mg/mL; 83.51 mM
Ethanol Max Solubility	1.8 mg/mL; 2.7 mM